AprilBio

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • USD 21.33M foreign currency net asset exposure, KRW 30.61B equivalent at fiscal year-end 2025
• • USD 1,333,158 cash and cash equivalents valued at KRW 1.91B, and USD 20M short-term financial products at KRW 28.7B at fiscal year-end 2025

Management Discussion & Analysis

• • Revenue KRW 2.172B (-92.11% YoY), operating loss KRW 7.264B vs prior operating profit KRW 16.87B, net loss KRW 9.728B vs prior net income KRW 20.01B
• • SAFA platform-driven pipeline with APB-A1 and APB-R3 licensing deals totaling over USD 892M, enabling first profitability post-IPO

Business Overview

• • 100% revenue from license-out of novel antibody and sustained-recombinant protein drug candidates in FY2025, including USD 475M deal with Evommune in June 2024
• • APB-R3 IL-18 binding fusion protein licensed to Evommune (6/20/2024), clinical 2a stage ongoing for atopic dermatitis since Feb 2025

What are the latest AprilBio DART filings in 2026?

AprilBio (KRX code 397030) has filed an annual report on March 13, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did AprilBio file its most recent annual report?

AprilBio filed its most recent annual report on March 13, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is AprilBio's KRX stock code?

AprilBio's KRX stock code is 397030. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 397030 to look up all AprilBio disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does AprilBio file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for AprilBio.

Where can I find AprilBio financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from AprilBio annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.